• Putting Data To Work In A Pandemic

    Even before the pandemic hit, clinical trials were beset by high failure rates. As the business begins to dig itself out of a pandemic-led slump, find out why sponsors need to know, now more than ever, where to find high performing sites and how to ensure that their enrollment and data collection efforts are on target.

  • Gene Expression In Some Fresh Brain Tissue Shown To Increase Activity After Death

    Recent research from the University of Illinois Chicago (UIC) reveals that some cells – brain cells, specifically – might even increase their activity after death and grow at an astonishing rate. To find out more about this research, read the available blog post.

  • Overcoming Three Investigator Training Challenges For Clinical Trials

    The clinical trial landscape has changed in ways that we couldn't have imagined two years ago. It has also brought to light key investigator training challenges and helped our industry embrace technology-enabled innovation to help overcome those obstacles. In this blog, explore three training challenges that clinical study teams face, along with solutions provided by on-demand virtual training.

  • Simplify To Accelerate: Perspectives On Moving Toward A More Collaborative Clinical Trial Ecosystem

    Read this white paper for perspectives from three parties—a sponsor, a site, and a technologist—to understand current challenges with information sharing and steps to improve collaboration in clinical trials.

  • CNS Trial Failure Rates High As Need For New Drugs Grows

    The need for CNS therapies has never been more acute, and there is a pressing need for both disease modifying and symptomatic treatments.

  • Placebo Considerations In Chronic Pain Studies

    There is a longstanding debate on the use of placebo control in clinical trials. Critics argue that it sacrifices the welfare of patients and is unethical if a proven therapy exists. Proponents argue that placebo control is crucial for proving the safety and efficacy of new treatments. This white paper reviews the regulatory, ethical, and cultural considerations surrounding the issue of placebo control in analgesia clinical trials and explores approaches to mitigating the placebo response.

  • Adaptive Trial Designs: Understanding The Potential Of Statistical Innovation

    Adaptive designs can be applied across all phases of clinical research, however guidance from experienced biostatisticians is critical to pairing the adaptive design option with development phase and trial objectives.

  • The Future Of Clinical Trials Is Here

    Cognizant Shared Investigator Platform (SIP) is a multi-sponsor collaborative solution for clinical trial site selection, start-up communications, and management. The open design of Cognizant SIP simplifies and accelerates clinical trials by eliminating redundant work for sponsors and clinical sites. This can lead to improved operating efficiencies, reduced costs of building and maintaining in-house technology, quicker study start up and more time spent with patients.

  • Conducting Clinical Trials During The COVID-19 Pandemic

    Join Mariska Beukers as she thoroughly discusses the clinical study subject flow during COVID-19. These slides follow their strategy as they entered a stay-at-home order, received the restart of clinical trails and developed a plan to open sites for clinical conduct.


  • With TrialScope Disclose, study sponsors streamline and optimize the entire clinical trial disclosure process from initial registration to final results — mitigating risk, maximizing transparency and ultimately moving healthcare forward.

  • At Q² Solutions, our dedicated, state-of-the-art Translational Science and Innovation Laboratory (TSAIL) is designed to  provide the agility and breadth of translational science capabilities and expertise required to bridge the gap between preclinical and early clinical drug development.

  • The only solution that offers both ride and reimbursement automation within one portal.

  • As a key element of study startup, IRB review can have a substantial impact on meeting critical study milestones. Advarra provides flexible solutions to help accelerate the initial IRB review process and make it more efficient.

  • With experience overseeing thousands of Phase I studies in the US and Canada, Advarra’s institutional review board (IRB) understands the unique requirements of Phase I study design and conduct. Our dedicated team and processes are built to support your Phase I research needs.